HeyJaredIona Everson
- Indexed articles, last 90 days
- 99
- Latest publication
- Oct 1, 2026
- Outlet visibility, for PMLiVE
- Top 5M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa - PMLiVE (opens the original)
Read excerpt
MSD, known as Merck in the US and Canada, has announced the first presentation of results from MK-7240-012, a phase 2b multicentre, randomised, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanised monoclonal antibody targeting tumour necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS). The results mark the first positive phase 2 data for an anti-TL1A monoclonal antibody in dermatology and the data will
Inizio Evoke appoints Brian Gundich as EVP, AI Enablement - PMLiVE (opens the original)
Read excerpt
Inizio Evoke has appointed Brian Gundich in the newly created role of EVP, AI Enablement, a role that reflects the agency’s sustained strategic investment in data, technology and AI. He is leading the integration of AI across the business: building an AI-enabled operating model with established governance, secure infrastructure and execution standards that turn investment into consistent, scalable value. Gundich is at the forefront of a business transformation designed to position the agency as
Inizio Evoke appoints Jake Vander Linden as President, Media - PMLiVE (opens the original)
Read excerpt
Inizio Evoke has appointed Jake Vander Linden as President, Media, where he leads media strategy, planning, activation, analytics and AdTech capabilities. He is responsible for advancing a more connected and predictive approach to media across the commercialisation life cycle. Vander Linden will further scale media strategy and activation with the agency’s proprietary behavioral intelligence, advanced analytics, and real-time performance signals—helping teams develop more inventive audience expe
Ogsiveo recommended by NICE to treat rare soft tissue tumours - PMLiVE (opens the original)
Read excerpt
Merck Healthcare has announced that Ogsiveo (nirogacestat) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat adults with progressing desmoid tumours who require systemic treatment. Desmoid tumours, also known as desmoid-type fibromatosis, are rare soft tissue tumours that have a reported annual incidence of approximately 2-4 cases per million people. In the UK, there are an estimated 340-410 new cases each year. They predominantly occur in adults aged
Heart, humanity and the work behind the words - PMLiVE (opens the original)
Read excerpt
As artificial intelligence continues to transform our industry, it is a question many of us are asking. Yet while the tools at our disposal are evolving rapidly, the qualities that define the best campaigns, programmes and communications remain remarkably unchanged. Behind every award-winning piece of work are people. People with ideas, passion, determination and, quite often, the patience to navigate countless rounds of feedback. Many of us arrived in this profession by unexpected routes. Some
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For PMLiVE, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.